- Home
- PLUR vs SCLX Comparison
PLUR vs SCLX Comparison
Compare PLUR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- SCLX
- Stock Information
- Founded
- PLUR 2001
- SCLX 2011
- Country
- PLUR Israel
- SCLX United States
- Employees
- PLUR N/A
- SCLX N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- SCLX Health Care
- Exchange
- PLUR Nasdaq
- SCLX Nasdaq
- Market Cap
- PLUR 41.9M
- SCLX 33.9M
- IPO Year
- PLUR N/A
- SCLX N/A
- Fundamental
- Price
- PLUR $5.48
- SCLX $6.38
- Analyst Decision
- PLUR Strong Buy
- SCLX Strong Buy
- Analyst Count
- PLUR 1
- SCLX 3
- Target Price
- PLUR $12.00
- SCLX $367.50
- AVG Volume (30 Days)
- PLUR 62.5K
- SCLX 96.4K
- Earning Date
- PLUR 05-13-2025
- SCLX 08-12-2025
- Dividend Yield
- PLUR N/A
- SCLX N/A
- EPS Growth
- PLUR N/A
- SCLX N/A
- EPS
- PLUR N/A
- SCLX N/A
- Revenue
- PLUR $1,034,000.00
- SCLX $50,710,000.00
- Revenue This Year
- PLUR $472.39
- SCLX $107.00
- Revenue Next Year
- PLUR $254.29
- SCLX $82.52
- P/E Ratio
- PLUR N/A
- SCLX N/A
- Revenue Growth
- PLUR 203.23
- SCLX 7.79
- 52 Week Low
- PLUR $3.33
- SCLX $3.60
- 52 Week High
- PLUR $7.13
- SCLX $73.50
- Technical
- Relative Strength Index (RSI)
- PLUR 59.69
- SCLX 60.64
- Support Level
- PLUR $4.61
- SCLX $6.00
- Resistance Level
- PLUR $5.96
- SCLX $6.76
- Average True Range (ATR)
- PLUR 0.56
- SCLX 0.42
- MACD
- PLUR 0.11
- SCLX 0.11
- Stochastic Oscillator
- PLUR 77.03
- SCLX 82.06
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.